Inicio
Markets
Charts & Ideas
Algo
Noticias
Store
Corredores
Descargar
Calendario económico
Señales Comerciales
WebTerminal
Pulse
/
para buscar: @user, $symbol, ...
Buscar
Entrada
Crear una cuenta
Español
English
Русский
中文
Português
日本語
Deutsch
한국어
Français
Italiano
Türkçe
PRTC
#5778
PureTech Health plc American Depositary Shares
16.7
7
+0.72%
Sector:
Básica:
Profit Currency:
Rango diario
Rango anual
Cambio diario
+0.72%
Monthly Change
-11.69%
6 month change
-4.17%
Cambio anual
-5.79%
Cierres anteriores
16.6
5
Open
17.0
0
Bid
Ask
Low
16.7
7
High
17.0
0
Volumen
2
Markets
Acciones
Atención Sanitaria
PRTC
Open full chart
Financials
Overview
Statement
Statistics
Dividends
Quarterly
Annual
Value
Q4, 24
TTM
Key stats
Total common shares outstanding
239.42 M
1.08 B
Valuation ratios
Enterprise value
4.42 B
—
Price to earnings ratio
—
—
Price to sales ratio
—
—
Price to cash flow ratio
—
—
Price to book ratio
—
—
Enterprise value to EBITDA ratio
—
—
Profitability ratios
Return on assets %
—
—
Return on equity %
—
—
Return on invested capital %
—
—
Gross margin %
—
—
Operating margin %
—
—
EBITDA margin %
—
—
Net margin %
—
—
Liquidity ratios
Quick ratio
—
—
Current ratio
—
—
Inventory turnover
—
—
Asset turnover
—
—
Solvency ratios
Debt to assets ratio
—
—
Debt to equity ratio
—
—
Long term debt to total assets ratio
—
—
Long term debt to total equity ratio
—
—
Per share metrics
Operating cash flow per share
—
—
EBIT per share
—
—
EBITDA per share
—
—
Total debt per share
—
—
Cash per share
—
—
Net current asset value per share
—
—
Tangible book value per share
—
—
Working capital per share
—
—
Book value per share
—
—
PureTech Health plc - American Depositary Shares
PureTech Health is an American biotechnology company which develops medicines to combat serious diseases. It is listed on the London Stock Exchange.
Noticias
Deupirfenidona recibe estatus de medicamento huérfano para enfermedad pulmonar rara
Deupirfenidona recibe estatus de fármaco huérfano para enfermedad pulmonar rara
Deupirfenidone receives orphan drug status for rare lung disease
La deupirfenidona de PureTech recibe estatus de fármaco huérfano de la FDA y la UE para FPI
Deupirfenidona de PureTech recibe estatus huérfano de FDA y UE para FPI
PureTech’s deupirfenidone receives FDA and EU orphan drug status for IPF
PureTech Health plc (PRTC) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
CEO de PureTech presentará en la Conferencia de Salud de J.P. Morgan
PureTech CEO to present at J.P. Morgan Healthcare Conference
PureTech Health nombra a Robert Lyne como CEO permanente
PureTech Health nombra a Robert Lyne como CEO permanente
PureTech Health appoints Robert Lyne as permanent CEO